Please assess the completion status of the following clinical trial:

Trial Title: Relapse-prevention Study With Lu AA21004 (Vortioxetine) in Patients With Generalized Anxiety Disorder

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~The patient has GAD as the primary diagnosis according to DSM-IV-TR criteria (classification code 300.02).~* The patient has a HAM-A total score \>=20 at screening and baseline visits~* The patient has a HAM-A score \>=2 on both Item 1 (anxious mood) and Item 2 (tension) at screening and baseline visits~* The patient has a MADRS total score \<=16 at screening and baseline visits~Exclusion Criteria:~* Any current psychiatric disorder other than GAD as defined in the DSM-IV-TR (assessed with the MINI)~* Any substance disorder (except nicotine and caffeine) within the previous 6 months as defined in the DSM-IV-TR~* Women of childbearing potential not using effective contraception~Other protocol-defined inclusion and exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Lu AA21004 (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).